Who in MGT actually knows what they are doing?

Quote
Whether the new debtors overpaid or not will be determined by the sales and marketing team achieving their goals. So instead of trying to be the smartest person on the board you should get out there selling your Makena. Also the hedge funds knew exactly what they were signing up for and their exit strategy is five years or five multiple. Maybe you should stop debating and go sell.
 






Anonymous said:
Whether the new debtors overpaid or not will be determined by the sales and marketing team achieving their goals. So instead of trying to be the smartest person on the board you should get out there selling your Makena. Also the hedge funds knew exactly what they were signing up for and their exit strategy is five years or five multiple. Maybe you should stop debating and go sell.
Click to expand...

Sell to who? Most of the docs won't see me, and the ones that do just want to hate on me for Makena's pricing. I wish Divis and/or SG would come with me on a few calls and see what it is really like out there. We are not liked.

Seems to me that this kind of feedback is not not making it back to HQ
 






Anonymous said:
Whether the new debtors overpaid or not will be determined by the sales and marketing team achieving their goals. So instead of trying to be the smartest person on the board you should get out there selling your Makena. Also the hedge funds knew exactly what they were signing up for and their exit strategy is five years or five multiple. Maybe you should stop debating and go sell.
Click to expand...

I've rarely seen a hedge fund investor group with the patience to wait 5 years, let alone 5 year multiples, in order to exit. Most try to exit with profit within a year to three.....if the first year does not meet financial goals they have been known to dump their investment, even at a loss, in order to stop the hemorrhage. KV/TherRx pipeline is non-existent and Evamist is a minor product, so the performance of the company is based almost solely on Makena. Makena is not doing that well in the marketplace (achieving only about 13% of potential market, at last public information available). The investor group that took KV/TherRx out of bankruptcy vastly overpaid for their rights to control the company. Without Makena achieving at least $120 Million per year, it is hard to see how the investor group could turn a profit within 1 to 3 years, let alone 5 years ("burn-through" is probably in excess of $75 Million/year, alone). Besides the Makena uptake performance, the likelihood of generic and NDA competition (same formula, different indication) is very high within the next 12 to 18 months. Additionally, docs are continuing to prescribe compounded 17-hydroxyprogesterone caproate injection over the branded Makena product. The poor KV/TherRx reputation is not helpful in improving the use of Makena. Management is doing basically nothing to try to improve it's image and reputation with OB/Gyn docs. Instead management focuses on new ways to try to stifle competition with legal wranglings that fail.
 






Anonymous said:
I've rarely seen a hedge fund investor group with the patience to wait 5 years, let alone 5 year multiples, in order to exit. Most try to exit with profit within a year to three.....if the first year does not meet financial goals they have been known to dump their investment, even at a loss, in order to stop the hemorrhage. KV/TherRx pipeline is non-existent and Evamist is a minor product, so the performance of the company is based almost solely on Makena. Makena is not doing that well in the marketplace (achieving only about 13% of potential market, at last public information available). The investor group that took KV/TherRx out of bankruptcy vastly overpaid for their rights to control the company. Without Makena achieving at least $120 Million per year, it is hard to see how the investor group could turn a profit within 1 to 3 years, let alone 5 years ("burn-through" is probably in excess of $75 Million/year, alone). Besides the Makena uptake performance, the likelihood of generic and NDA competition (same formula, different indication) is very high within the next 12 to 18 months. Additionally, docs are continuing to prescribe compounded 17-hydroxyprogesterone caproate injection over the branded Makena product. The poor KV/TherRx reputation is not helpful in improving the use of Makena. Management is doing basically nothing to try to improve it's image and reputation with OB/Gyn docs. Instead management focuses on new ways to try to stifle competition with legal wranglings that fail.
Click to expand...

VC and hedge fund exit times vary and the standard is 3-5 years or 3-5 multiple. Not one year, you are wrong. Also there a five debtors in play here for KV which means the risk is mitigated which provides more time and tolerance for management's Makena marketing plan to be executed successfully. The competitors haven't changed and the future landscape is never predictable as approval dates are always a moving target. What other strategies would you put in place against the compounding pharmacies? Look, the new KV will be fine and they will succeed despite the bashers offering nothing but negativity and b.s. Go sell Makena and stop your crying.
 






Anonymous said:
VC and hedge fund exit times vary and the standard is 3-5 years or 3-5 multiple. Not one year, you are wrong. Also there a five debtors in play here for KV which means the risk is mitigated which provides more time and tolerance for management's Makena marketing plan to be executed successfully. The competitors haven't changed and the future landscape is never predictable as approval dates are always a moving target. What other strategies would you put in place against the compounding pharmacies? Look, the new KV will be fine and they will succeed despite the bashers offering nothing but negativity and b.s. Go sell Makena and stop your crying.
Click to expand...

Signed,

Get-A-Clue
 






Anonymous said:
VC and hedge fund exit times vary and the standard is 3-5 years or 3-5 multiple. Not one year, you are wrong. Also there a five debtors in play here for KV which means the risk is mitigated which provides more time and tolerance for management's Makena marketing plan to be executed successfully. The competitors haven't changed and the future landscape is never predictable as approval dates are always a moving target. What other strategies would you put in place against the compounding pharmacies? Look, the new KV will be fine and they will succeed despite the bashers offering nothing but negativity and b.s. Go sell Makena and stop your crying.
Click to expand...

I did say that the VCs/hedge funds do try to "...exit with profit within a year to three". However, if the financial performance is not there in year one, you can almost bet that the investors will take steps to bail out.

The competitors ARE changing (look at clinicaltrials.gov) and you'll see what's pending regarding similar Makena formulations, including NDA clinical studies for a different indication that the docs could use "off-label" instead of Makena. In any event, the major obstacles to Makena use is still price. It seems to me that KV/TherRx could address the perceived predatory pricing of Makena by lowering the price now to a reasonable level. This strategy, now, would also thwart competition that may arise from ANDA or NDA approvals in the future.

Consider that most docs feel that the compounding pharmacy that they are using has a better reputation than does KV/TherRx. Seems to me that a key strategy to improve Makena use is to address the reputation issues at KV/TherRx, not the compounding pharmacies.
 












Anonymous said:
I did say that the VCs/hedge funds do try to "...exit with profit within a year to three". However, if the financial performance is not there in year one, you can almost bet that the investors will take steps to bail out.

The competitors ARE changing (look at clinicaltrials.gov) and you'll see what's pending regarding similar Makena formulations, including NDA clinical studies for a different indication that the docs could use "off-label" instead of Makena. In any event, the major obstacles to Makena use is still price. It seems to me that KV/TherRx could address the perceived predatory pricing of Makena by lowering the price now to a reasonable level. This strategy, now, would also thwart competition that may arise from ANDA or NDA approvals in the future.

Consider that most docs feel that the compounding pharmacy that they are using has a better reputation than does KV/TherRx. Seems to me that a key strategy to improve Makena use is to address the reputation issues at KV/TherRx, not the compounding pharmacies.
Click to expand...


Mr. Fix It back to his old rap of just fix the "reputation" because this is the solution to KV's challenges. I'm betting you are wanting a campaign of sorts, apologizing for some failures on pricing and such. Again you reveal your lack of true business acumen. KV has to work with the present circumstances of their business and deliver on the plan they've developed to meet their financial obligations to the new debtors. Fixing a perception on reputation is not going to deliver the results they need this year or this quarter. Wake up and get in the real business world. For KV to be successful they must work with the real world business facts of where they are today in terms of execution. customer access, and delivering results. KV has their plan in place and they are progressing as planned you can now go back to not selling and go back to dreamland.
 






Anonymous said:
Mr. Fix It back to his old rap of just fix the "reputation" because this is the solution to KV's challenges. I'm betting you are wanting a campaign of sorts, apologizing for some failures on pricing and such. Again you reveal your lack of true business acumen. KV has to work with the present circumstances of their business and deliver on the plan they've developed to meet their financial obligations to the new debtors. Fixing a perception on reputation is not going to deliver the results they need this year or this quarter. Wake up and get in the real business world. For KV to be successful they must work with the real world business facts of where they are today in terms of execution. customer access, and delivering results. KV has their plan in place and they are progressing as planned you can now go back to not selling and go back to dreamland.
Click to expand...

You don't understand that most of the OB/GYN docs, the ones that could prescribe Makena, won't prescribe the product and won't even see TherRx reps because of the really poor reputation that KV /TherRx has.
The best business plan that could be conceived is destined to fail, if the prescribing physicians can't be convinced that KV/TherRx seen the errors in their ways and behaves contritely. If you think gaining about 14% of the potential market for Makena is "...delivering results", then surely you are blind to the fact that the execution plan is failing.

The reputation of the company needs to be "fixed" and fast, this year, or the company is doomed. One way would be to lower the price of Makena, admit that it's pricing strategy was not smart, and stop filing unwinable lawsuits against governmental agencies.
 






Anonymous said:
You don't understand that most of the OB/GYN docs, the ones that could prescribe Makena, won't prescribe the product and won't even see TherRx reps because of the really poor reputation that KV /TherRx has.
The best business plan that could be conceived is destined to fail, if the prescribing physicians can't be convinced that KV/TherRx seen the errors in their ways and behaves contritely. If you think gaining about 14% of the potential market for Makena is "...delivering results", then surely you are blind to the fact that the execution plan is failing.

The reputation of the company needs to be "fixed" and fast, this year, or the company is doomed. One way would be to lower the price of Makena, admit that it's pricing strategy was not smart, and stop filing unwinable lawsuits against governmental agencies.
Click to expand...


Your response says it all.

You have already given up and failed.

Hopefully Ther-Rx can get you out the door as quickly as possible.
 






Anonymous said:
Your response says it all.

You have already given up and failed.

Hopefully Ther-Rx can get you out the door as quickly as possible.
Click to expand...

I guess that's the TherRx way, in your vision. All Makena campaign failure is blamed on the reps. Scoot out any rep who should try to understand why these OB/Gyn docs literally "hate" TherRx. It's pretty clear to me that until TherRx does something substantial to improve it's reputation generally, and remove the predatory pricing of Makena, the company and its efforts are doomed.
 






Anonymous said:
I guess that's the TherRx way, in your vision. All Makena campaign failure is blamed on the reps. Scoot out any rep who should try to understand why these OB/Gyn docs literally "hate" TherRx. It's pretty clear to me that until TherRx does something substantial to improve it's reputation generally, and remove the predatory pricing of Makena, the company and its efforts are doomed.
Click to expand...

We need everyone fighting for every new available patient and you have already resigned position, at least mentally, which means you need to leave. It's ok there are other jobs out there just move on so you don't drag the rest of us down.
 






Anonymous said:
We need everyone fighting for every new available patient and you have already resigned position, at least mentally, which means you need to leave. It's ok there are other jobs out there just move on so you don't drag the rest of us down.
Click to expand...

Maybe you are right and that I should leave. But, I'm not a quitter. I've worked hard to develop lasting relationships, where possible, that have have resulted in scripts. I'd rather try to expend some effort on trying to get management to appreciate the bad reputation that the company has with the docs, rather than wrap it up and leave right now.

It bothers me that management can't see or appreciate the the major obstacle to the success of Makena, namely that the docs literally "hate" us and the company based on the price of Makena and the bad juju that the company has been spreading regarding the compounded versions of Makena. These docs have been using the compounded versions for many years and have confidence in the compounding pharmacies they are using. In contrast, their view of KV/TherRx's reputation is not so hot. Seems to me, down in the so-called trenches, that Makena will not achieve its market potential until the company does something dramatic to overcome its poor reputation.

I can agree with you, in that if management can't even appreciate the reputation issues, then it is time for me to leave.
 






Anonymous said:
Maybe you are right and that I should leave. But, I'm not a quitter. I've worked hard to develop lasting relationships, where possible, that have have resulted in scripts. I'd rather try to expend some effort on trying to get management to appreciate the bad reputation that the company has with the docs, rather than wrap it up and leave right now.

It bothers me that management can't see or appreciate the the major obstacle to the success of Makena, namely that the docs literally "hate" us and the company based on the price of Makena and the bad juju that the company has been spreading regarding the compounded versions of Makena. These docs have been using the compounded versions for many years and have confidence in the compounding pharmacies they are using. In contrast, their view of KV/TherRx's reputation is not so hot. Seems to me, down in the so-called trenches, that Makena will not achieve its market potential until the company does something dramatic to overcome its poor reputation.

I can agree with you, in that if management can't even appreciate the reputation issues, then it is time for me to leave.
Click to expand...

When can we expect your resignation? Or will you become another double dipper?
 






Anonymous said:
We need everyone fighting for every new available patient and you have already resigned position, at least mentally, which means you need to leave. It's ok there are other jobs out there just move on so you don't drag the rest of us down.
Click to expand...

Gosh Divis you are such a motivator!!! WHY DON'T YOU RESIGN AND MOVE ON YOU PINHEAD!!!!! Maybe this company will actually recover from the fiasco you put it through. Good grief you are such a, and I'm using your words, a "whiney" person.
 


















Anonymous said:
When can we expect your resignation? Or will you become another double dipper?
Click to expand...

I don't think I could "double dip". I have this ethics problem that my parents gave me growing up. However, it sure would be easy, since most docs are so pissed with TherRx they either won't see me at all, or give me about 20 seconds of facetime. Lot's of opportunity to have time to detail other products in the same building, yet meet TherRx's detailing plan.
 






Top Bottom
Back
Quote